fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
fuga mobilya
The Official Website for the SFJ Pharmaceuticals Group
   

In The News

The SFJ Pharmaceuticals Group announces agreement with Pfizer to co-develop Dacomitnib as first-line treatment for patients with advances non-small cell cancer.

View the Press Release


Welcome To SFJ Pharmaceuticals Group

The SFJ Pharmaceuticals Group is a Specialty Pharma Company deploying a new business model for the clinical development and registration of pharmaceutical products.

SFJ Pharmaceuticals Group provides a financially advantageous and creative alternative approach to partnering. SFJ Pharmaceuticals Group can provide the strategic financing, clinical development and regulatory resources for the clinical development and approval of your products.


SFJ Pharmaceuticals Group is staffed with a seasoned team of professionals, with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis.

SFJ Pharmaceuticals Group has offices in the United States, Japan, Singapore and Korea with Asia specific clinical development and regulatory experts to help you develop your pharmaceutical products for Japan, China and other Asian countries.




 

Mission

The SFJ Pharmaceuticals Group mission is to accelerate the availability of new and innovative drugs into the world's major markets, by providing not only additional funding, but also strategic development expertise to enable our Pharma and Biotech partners to be as hands off or as hands on as they wish.

Target Market

SFJ Pharmaceuticals Group is primarily focused on funding and / or executing global or regional Phase III studies.

SFJ Pharmaceuticals Group is positioned to develop prescription drugs in any and all therapeutic areas, where there is a clear medical and market need.